High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab

IntroductionWe report herein the case of a patient diagnosed with high-risk neuroblastoma (HR-NB), treated with naxitamab following suboptimal response to induction chemotherapy, becoming the first patient to receive this therapy at the National Institute of Pediatrics (INP) in Mexico. We discuss th...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alberto Olaya Vargas, Haydee Salazar-Rosales, Marcela Caballero-Palacios, Nideshda Ramírez-Uribe, Gerardo López-Hernández, Erika Morales-Martinez, María Cervantes-Delgado, Liliana Velasco Hidalgo, Araceli Castellanos-Toledo, Rocío Cárdenas-Cardos, Ana Niembro-Zúñiga, Roberto Rivera-Luna, Alberto Olaya-Nieto, Jesús Ponce-Cruz, Jaime Shalkow-Klincovstein, Yadira Melchor-Vidal, Rodrigo Díaz-Machorro
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Oncology
Subjects:	high-risk neuroblastoma immunotherapy naxitamab Latin America pediatric cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1520171/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab

Similar Items